NASDAQ:EXAI Exscientia (EXAI) Stock Price, News & Analysis → Truth about Trump you’ve never heard (From Porter & Company) (Ad) Free EXAI Stock Alerts $5.30 +0.36 (+7.29%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$4.93▼$5.4750-Day Range$3.99▼$5.9452-Week Range$3.86▼$9.12Volume725,629 shsAverage Volume656,524 shsMarket Capitalization$640.72 millionP/E RatioN/ADividend YieldN/APrice Target$9.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Exscientia MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside87.9% Upside$9.75 Price TargetShort InterestHealthy3.66% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.40Based on 18 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.07) to ($1.04) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.96 out of 5 starsMedical Sector690th out of 929 stocksBiological Products, Except Diagnostic Industry117th out of 153 stocks 3.3 Analyst's Opinion Consensus RatingExscientia has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageExscientia has only been the subject of 1 research reports in the past 90 days.Read more about Exscientia's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.66% of the float of Exscientia has been sold short.Short Interest Ratio / Days to CoverExscientia has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Exscientia has recently decreased by 0.91%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldExscientia does not currently pay a dividend.Dividend GrowthExscientia does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EXAI. Previous Next 2.4 News and Social Media Coverage News SentimentExscientia has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Exscientia this week, compared to 3 articles on an average week.Search Interest12 people have searched for EXAI on MarketBeat in the last 30 days. This is an increase of 9% compared to the previous 30 days.MarketBeat FollowsOnly 26 people have added Exscientia to their MarketBeat watchlist in the last 30 days. This is a decrease of -7% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Exscientia insiders have not sold or bought any company stock.Percentage Held by Insiders16.40% of the stock of Exscientia is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions41.58% of the stock of Exscientia is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Exscientia's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Exscientia are expected to grow in the coming year, from ($1.07) to ($1.04) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Exscientia is -3.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Exscientia is -3.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioExscientia has a P/B Ratio of 1.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Exscientia's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Freeport SocietyNext President (Not Trump. Not Biden.)Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be Trump.Click here to see why it will be ______ _________. About Exscientia Stock (NASDAQ:EXAI)Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.Read More EXAI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EXAI Stock News HeadlinesMay 31 at 5:07 PM | prnewswire.comEXAI Investors Have Opportunity to Lead Exscientia p.l.c. Securities Fraud LawsuitMay 31 at 11:10 AM | prnewswire.comDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ExscientiaMay 30 at 4:45 PM | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Exscientia p.l.c. of Class Action Lawsuit and Upcoming Deadlines - EXAIMay 30 at 4:05 PM | prnewswire.comROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Exscientia p.l.c Investors to Secure Counsel Before Important Deadline in Securities Class Action - EXAIMay 30 at 2:10 PM | businesswire.comBanyanGlobal Family Business Advisors Elects Ben Francois as New Managing PartnerMay 30 at 2:00 PM | businesswire.comInszone Insurance Services Strengthens Presence in Coachella Valley with Acquisition of John Henry InsuranceMay 30 at 7:00 AM | businesswire.comExscientia to Present at Upcoming Investor Conferences in JuneMay 30 at 5:50 AM | prnewswire.comExscientia plc Sued for Securities Law Violations - Contact Levi & Korsinsky Before June 25, 2024 to Discuss Your Rights - EXAIMay 29 at 4:23 PM | stockhouse.comTOP RANKED ROSEN LAW FIRM Encourages Exscientia p.l.c Investors to Secure Counsel Before Important Deadline in Securities Class Action - EXAIMay 29 at 5:45 AM | prnewswire.comExscientia plc Sued for Securities Law Violations - Contact The Gross Law Firm Before June 25, 2024 to Discuss Your Rights - EXAIMay 28 at 10:53 PM | markets.businessinsider.comIMPORTANT SHAREHOLDER NOTICE: The Schall Law Firm Encourages Investors in Exscientia plc with Losses to Contact the FirmMay 28 at 12:00 PM | prnewswire.comEXAI Investors Have Opportunity to Lead Exscientia p.l.c. Securities Fraud LawsuitMay 25, 2024 | markets.businessinsider.comDEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Exscientia plc with Losses to Contact the FirmMay 25, 2024 | finance.yahoo.comAnalysts Are Upgrading Exscientia plc (NASDAQ:EXAI) After Its Latest ResultsMay 25, 2024 | americanbankingnews.comExscientia (NASDAQ:EXAI) Shares Gap Down to $4.95May 24, 2024 | stockhouse.comINVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Exscientia plc with Losses to Contact the FirmMay 23, 2024 | investorplace.comThe 3 Best Machine Learning Stocks to Quadruple Your Money by 2035May 23, 2024 | prnewswire.comJune 25, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against EXAIMay 22, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Exscientia p.l.c. of Class Action Lawsuit and Upcoming Deadlines - EXAIMay 22, 2024 | prnewswire.comROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Exscientia p.l.c Investors to Secure Counsel Before Important Deadline in Securities Class Action - EXAIMay 22, 2024 | markets.businessinsider.comDEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ExscientiaMay 22, 2024 | seekingalpha.comExscientia: Drug Discovery Platform Attracting Partners And CashMay 21, 2024 | prnewswire.comEXAI Investors Have Opportunity to Lead Exscientia p.l.c. Securities Fraud LawsuitMay 21, 2024 | investorplace.comEXAI Stock Earnings: Exscientia Beats EPS, Misses Revenue for Q1 2024May 21, 2024 | businesswire.comExscientia Business Update for First Quarter 2024See More Headlines Company Calendar Last Earnings3/21/2024Today5/31/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:EXAI CUSIPN/A CIK1865408 Webwww.exscientia.ai Phone44-0-18-6581-8941FaxN/AEmployees483Year FoundedN/APrice Target and Rating Average Stock Price Target$9.75 High Stock Price Target$13.00 Low Stock Price Target$7.00 Potential Upside/Downside+85.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-181,560,000.00 Net Margins-666.80% Pretax Margin-737.98% Return on Equity-34.59% Return on Assets-24.67% Debt Debt-to-Equity Ratio0.05 Current Ratio6.30 Quick Ratio6.30 Sales & Book Value Annual Sales$25.60 million Price / Sales24.89 Cash FlowN/A Price / Cash FlowN/A Book Value$3.47 per share Price / Book1.52Miscellaneous Outstanding Shares120,890,000Free Float101,062,000Market Cap$637.09 million OptionableOptionable Beta0.82 Key ExecutivesDr. David Hallett Ph.D. (Age 55)Chief Scientific Officer, Interim CEO, Principal Executive Officer & Executive Director Mr. Ben R. Taylor (Age 47)CFO, Chief Strategy Officer & Executive Director Comp: $534.97kDr. Michael Krams M.D. (Age 63)Chief Medical Officer Ms. Eileen Jennings-BrownChief Information OfficerMs. Sara ShermanVice President of Investor RelationsMr. Dan IrelandExecutive VP of Legal & Company SecretaryMr. Parker MossExecutive Vice President of Corporate DevelopmentMs. Caroline RowlandChief People OfficerMr. Richard LawChief Business OfficerDr. John P. Overington Ph.D.Chief Data OfficerMore ExecutivesKey CompetitorsAbCellera BiologicsNASDAQ:ABCLSchrödingerNASDAQ:SDGRADMA BiologicsNASDAQ:ADMACG OncologyNASDAQ:CGONRecursion PharmaceuticalsNASDAQ:RXRXView All CompetitorsInstitutional OwnershipPlatinum Investment Management Ltd.Sold 141,500 shares on 5/14/2024Ownership: 3.265%EntryPoint Capital LLCBought 5,784 shares on 5/14/2024Ownership: 0.026%Mitsubishi UFJ Trust & Banking CorpSold 25,530 shares on 5/10/2024Ownership: 0.125%Susquehanna Portfolio Strategies LLCSold 13,169 shares on 5/7/2024Ownership: 0.028%Baillie Gifford & Co.Sold 116,075 shares on 5/1/2024Ownership: 3.784%View All Institutional Transactions EXAI Stock Analysis - Frequently Asked Questions Should I buy or sell Exscientia stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Exscientia in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" EXAI shares. View EXAI analyst ratings or view top-rated stocks. What is Exscientia's stock price target for 2024? 4 brokerages have issued twelve-month target prices for Exscientia's shares. Their EXAI share price targets range from $7.00 to $13.00. On average, they predict the company's share price to reach $9.75 in the next twelve months. This suggests a possible upside of 87.9% from the stock's current price. View analysts price targets for EXAI or view top-rated stocks among Wall Street analysts. How have EXAI shares performed in 2024? Exscientia's stock was trading at $6.41 at the beginning of the year. Since then, EXAI shares have decreased by 19.0% and is now trading at $5.19. View the best growth stocks for 2024 here. When is Exscientia's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our EXAI earnings forecast. How were Exscientia's earnings last quarter? Exscientia plc (NASDAQ:EXAI) announced its quarterly earnings data on Thursday, March, 21st. The company reported ($0.42) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.44) by $0.02. The firm earned $3.10 million during the quarter, compared to the consensus estimate of $41.63 million. Exscientia had a negative net margin of 666.80% and a negative trailing twelve-month return on equity of 34.59%. What ETF holds Exscientia's stock? First Trust Nasdaq Artificial Intelligence and Robotics ETF holds 1,443,583 shares of EXAI stock, representing 1.32% of its portfolio. When did Exscientia IPO? Exscientia (EXAI) raised $291 million in an IPO on Friday, October 1st 2021. The company issued 13,850,000 shares at $20.00-$22.00 per share. Who are Exscientia's major shareholders? Exscientia's stock is owned by many different institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (3.78%), Platinum Investment Management Ltd. (3.26%), Mitsubishi UFJ Trust & Banking Corp (0.13%), Susquehanna Portfolio Strategies LLC (0.03%), EntryPoint Capital LLC (0.03%) and China Universal Asset Management Co. Ltd. (0.01%). How do I buy shares of Exscientia? Shares of EXAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EXAI) was last updated on 5/31/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressShocking $16T Elon Musk Crypto LeakCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarWho are Nvidia’s New Silent Partners?Weiss RatingsMissed NVDA? Buy this AI stock NOWChaikin Analytics41 banks launch ‘crypto dollar’Stansberry ResearchGold Set to EXPLODE!Gold Safe ExchangeDo This Before July 30 2024 To Claim Trump’s Gift Wealthpin Pro Adding Choose a watchlist: Watchlist My Default Watchlist Adding Exscientia plc You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.